Biased opioid ligands

A Faouzi, BR Varga, S Majumdar - Molecules, 2020 - mdpi.com
Achieving effective pain management is one of the major challenges associated with
modern day medicine. Opioids, such as morphine, have been the reference treatment for …

Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders

A Newman-Tancredi, RY Depoortère… - Pharmacology & …, 2022 - Elsevier
Biased agonism (or “functional selectivity”) at G-protein-coupled receptors has attracted
rapidly increasing interest as a means to improve discovery of more efficacious and safer …

Pharmacological data of cannabidiol-and cannabigerol-type phytocannabinoids acting on cannabinoid CB1, CB2 and CB1/CB2 heteromer receptors

G Navarro, K Varani, A Lillo, F Vincenzi… - Pharmacological …, 2020 - Elsevier
Background Recent approved medicines whose active principles are Δ 9
Tetrahidrocannabinol (Δ 9-THC) and/or cannabidiol (CBD) open novel perspectives for …

Recent advances in dopamine D2 receptor ligands in the treatment of neuropsychiatric disorders

R Juza, K Musilek, E Mezeiova… - Medicinal Research …, 2023 - Wiley Online Library
Dopamine is a biologically active amine synthesized in the central and peripheral nervous
system. This biogenic monoamine acts by activating five types of dopamine receptors (D1 …

Recent advances in the potential of cannabinoids for neuroprotection in Alzheimer's, Parkinson's, and Huntington's diseases

C Pérez-Olives, R Rivas-Santisteban, J Lillo… - Cannabinoids and …, 2020 - Springer
Three prevalent neurodegenerative diseases, Parkinson's, Alzheimer's, and Huntington's
are in need of symptomatic relief of slowing disease progression or both. This chapter …

Adenosine A2A Receptor Antagonists Affects NMDA Glutamate Receptor Function. Potential to Address Neurodegeneration in Alzheimer's Disease

R Franco, R Rivas-Santisteban, M Casanovas, A Lillo… - Cells, 2020 - mdpi.com
(1) Background. N-methyl d-aspartate (NMDA) ionotropic glutamate receptor (NMDAR),
which is one of the main targets to combat Alzheimer's disease (AD), is expressed in both …

Pharmacological potential of varinic-, minor-, and acidic phytocannabinoids

R Franco, R Rivas-Santisteban, I Reyes-Resina… - Pharmacological …, 2020 - Elsevier
While natural Δ 9-tetrahidrocannabinol (Δ 9 THC), cannabidiol (CBD), and their therapeutic
potential have been extensively researched, some cannabinoids have been less extensively …

[HTML][HTML] Similarities and differences upon binding of naturally occurring Δ9-tetrahydrocannabinol-derivatives to cannabinoid CB1 and CB2 receptors

I Raïch, R Rivas-Santisteban, A Lillo, J Lillo… - Pharmacological …, 2021 - Elsevier
We have here assessed, using Δ 9-tetrahydrocannabinol (Δ 9-THC) for comparison, the
effect of Δ 9-tetrahydrocannabinolic acid (Δ 9-THCA) and of Δ 9-tetrahydrocannabivarin (Δ9 …

N-Methyl-D-aspartate (NMDA) and cannabinoid CB2 receptors form functional complexes in cells of the central nervous system: insights into the therapeutic potential …

R Rivas-Santisteban, A Lillo, J Lillo… - Alzheimer's Research & …, 2021 - Springer
Background The cannabinoid CB 2 receptor (CB 2 R), which is a target to afford
neuroprotection, and N-methyl-D-aspartate (NMDA) ionotropic glutamate receptors, which …

Historical perspectives and recent advances in small molecule ligands of selective/biased/multi-targeted μ/δ/κ opioid receptor (2019–2022)

Y He, Q Su, L Zhao, L Zhang, L Yu, J Shi - Bioorganic Chemistry, 2023 - Elsevier
The opioids have been used for more than a thousand years and are not only the most
widely prescribed drugs for moderate to severe pain and acute pain, but also the preferred …